The domain within your query sequence starts at position 546 and ends at position 1014; the E-value for the Glyco_transf_41 domain shown below is 2.6e-280.

LRVGYVSSDFGNHPTSHLMQSIPGMHNPDKFEVFCYALSPDDGTNFRVKVMAEANHFIDL
SQIPCNGKAADRIHQDGIHILVNMNGYTKGARNELFALRPAPIQAMWLGYPGTSGALFMD
YIITDQETSPAEVAEQYSEKLAYMPHTFFIGDHANMFPHLKKKAVIDFKSNGHIYDNRIV
LNGIDLKAFLDSLPDVKIVKMKCPDGGDNPDSSNTALNMPVIPMNTIAEAVIEMINRGQI
QITINGFSISNGLATTQINNKAATGEEVPRTIIVTTRSQYGLPEDAIVYCNFNQLYKIDP
STLQMWANILKRVPNSVLWLLRFPAVGEPNIQQYAQNMGLPQNRIIFSPVAPKEEHVRRG
QLADVCLDTPLCNGHTTGMDVLWAGTPMVTMPGETLASRVAASQLTCLGCLELIAKSRQE
YEDIAVKLGTDLEYLKKIRGKVWKQRISSPLFNTKQYTMELERLYLQMW

Glyco_transf_41

Glyco_transf_41
PFAM accession number:PF13844
Interpro abstract (IPR029489):

This entry represents the C-terminal domain of the O-linked beta-N-acetylglucosamine transferase (OGT, also known as UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase), which catalyses the transfer of a single GlcNAc to the Ser or Thr of nucleocytoplasmic proteins [ (PUBMED:18948359) ]. OGTs have two known domains: the N-terminal tetratricopeptide repeat domain and the C-terminal glycosyltransferase domain [ (PUBMED:18536723) ]. Deletions of the C-terminal domain result in a complete loss of the enzyme activity [ (PUBMED:10753899) ].

In animals, OGT is an essential protein that modifies transcription factors, nuclear pore proteins, kinases, and many other proteins. Abnormalities in OGT activities have been associated with type 2 diabetes [ (PUBMED:18288188) ].

This is a PFAM domain. For full annotation and more information, please see the PFAM entry Glyco_transf_41